Nkarta
NKTX55
$2.56arrow_drop_down6.29%-$0.17
Penny Stock
NKTX55
$2.56
arrow_drop_down6.29%Performance History
| Key Stats | |
|---|---|
| Open | $2.90 |
| Prev. Close | $2.91 |
| EPS | -1.83 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $203.37M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 2.79 | 2.93 |
| 52 Week Range | 1.32 | 16.24 |
| Ratios | |
|---|---|
| Revenue | - |
| EBITDA Margin % | - |
| EPS | -1.83 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Nkarta (NKTX)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Paul J. Hastings
- Headquarters
- South San Francisco
- Employees
- 169
- Exchange
- NASDAQ
Keep an eye on Nkarta
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Nkarta 's (NKTX) price per share?
The current price per share for Nkarta (NKTX) is $2.56. The stock has seen a price change of -$0.17 recently, indicating a -6.3% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Nkarta (NKTX)?
For Nkarta (NKTX), the 52-week high is $16.24, which is 534.37% from the current price. The 52-week low is $1.32, the current price is 93.94% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Nkarta (NKTX) a growth stock?
Nkarta (NKTX) has shown an average price growth of -4.94% over the past three years. It has received a score of 10 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Nkarta as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Nkarta (NKTX) stock price performance year to date (YTD)?
As of the latest data, Nkarta (NKTX) has a year-to-date price change of -59.81%. Over the past month, the stock has experienced a price change of -35.03%. Over the last three months, the change has been -50.1%. Over the past six months, the figure is -60.92%.
help
Is Nkarta (NKTX) a profitable company?
Nkarta (NKTX) has a net income of -$117.5M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$131.65M. Furthermore, the EBITDA is -$118.14M.
help
What is the market capitalization of Nkarta (NKTX)?
Nkarta (NKTX) has a market capitalization of $178.54M. The average daily trading volume is 2.57, indicating the stock's liquidity and investor engagement.
News
NKARTA
NATURAL KILLER CELL THERAPIES
INVESTOR CONFERENCE
Nkarta to Participate in Upcoming Investor Conference
NKARTA
NKX019
AUTOIMMUNE DISEASES
RAYMOND JAMES
Why Nkarta Stock Is Soaring Today
NKARTA
LEADERSHIP CHANGES
AUTOIMMUNE DISEASE
CAR NK CELL THERAPY
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President - GlobeNewswire
HEALTH
CLINICAL STUDY
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
DIRECTORS AND OFFICERS
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
EARNINGS RELEASES AND OPERATING RESULTS
CONFERENCE CALLS/ WEBCASTS
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights